TDC
ARIA

Thompson Davis & Co’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Thompson Davis & Co’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-250
Closed -$3K – 1279
2016
Q3 		$3K Buy
+250
New +$2.51K 0.01% 976
2014
Q4 		– Sell
-500
Closed -$3K – 1339
2014
Q3 		$3K Hold
500
– – ﹤0.01% 1028
2014
Q2 		$3K Hold
500
– – ﹤0.01% 707
2014
Q1 		$4K Buy
+500
New +$3.89K 0.01% 692

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Thompson Davis & Co's ARIA Position: Q4 2016 in Review

Thompson Davis & Co sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2016, closing a stake of 250 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in ARIA in Q1 2014 and held it in 4 quarters. The position peaked at $4K in Q1 2014. 200 funds tracked by Wall St. Rank hold ARIA as of Q4 2016.

  • Thompson Davis & Co reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 250 Ariad Pharmaceuticals Inc shares in Q4 2016, an estimated $3K.
  • Thompson Davis & Co first reported a position in Ariad Pharmaceuticals Inc in Q1 2014 and held it in 4 quarters.
  • Thompson Davis & Co's Ariad Pharmaceuticals Inc position peaked at $4K in Q1 2014.
  • 200 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.